REFERENCES
- Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352(17)1779–1790, [INFOTRIEVE]
- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365(9464)1054–1061, [INFOTRIEVE]
- James C, Ugo V, LeCouedic J-P, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434(7037)1144–1148, [INFOTRIEVE], [CROSSREF]
- McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20(1)168–171, [INFOTRIEVE]
- Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gillilland DG, Druker B, Deininger MWN. The JAK2V617F activating mutation in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106(10)3377–3379, [INFOTRIEVE], [CROSSREF]
- Hoyer JD, Weinhold J, Mailhot E, Alter D, McCormick DJ, Snow K, Kubik KS, Holmes MW, Fairbanks VF. Three new hemoglobin variants with abnormal oxygen affinity: Hb Saratoga Springs [α40(C5)Lys→Asn (α1)], Hb Santa Clara [β97(FG4)His→Asn], and Hb Sparta [β103(G5)Phe→Val]. Hemoglobin 2003; 27(4)235–241, [INFOTRIEVE], [CROSSREF]